Literature DB >> 24555660

Frequency of the transthyretin Val30Met mutation in the northern Swedish population.

Malin Olsson1, Jenni Jonasson, Kristina Cederquist, Ole B Suhr.   

Abstract

By genotyping a large number of samples from the Northern Sweden Health and Disease Study cohort, a carrier frequency could be determined for the Skellefteå and Lycksele populations. A previous study of the amyloidogenic transthyretin mutation TTRV30M in Northern Sweden's endemic area has shown a large variation in carrier frequency and penetrance of the trait within the area. However, the estimations have been based on a small sample size within the different regions in the area and therefore, the wide variation in TTRV30M carrier frequency observed between the Lycksele and Skellefteå populations are uncertain. Based on a total of 3460 samples, the estimated overall carrier frequency in the two regions was 1.82% with a carrier frequency in the Skellefteå and Lycksele population of 1.63% and 2.02%, respectively. Thus, the previously reported extremely high frequency in the Lycksele region compared to that of the Skellefteå region could not be substantiated. However, it does not change the previous finding of a surprisingly higher carrier frequency in the population from endemic area of Northern Sweden compared to that reported from endemic areas in Portugal.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24555660     DOI: 10.3109/13506129.2013.860027

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  5 in total

1.  Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas.

Authors:  Andreas Thimm; Saskia Bolz; Michael Fleischer; Benjamin Stolte; Sebastian Wurthmann; Andreas Totzeck; Alexander Carpinteiro; Peter Luedike; Maria Papathanasiou; Christoph Rischpler; Ken Herrmann; Tienush Rassaf; Lars Steinmüller-Magin; Christoph Kleinschnitz; Tim Hagenacker
Journal:  Neurol Res Pract       Date:  2019-09-18

2.  Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.

Authors:  Volha Skrahina; Ulrike Grittner; Christian Beetz; Thomas Skripuletz; Martin Juenemann; Heidrun H Krämer; Katrin Hahn; Andreas Rieth; Volker Schaechinger; Monica Patten; Christian Tanislav; Stephan Achenbach; Birgit Assmus; Fabian Knebel; Stefan Gingele; Aliaksandr Skrahin; Jörg Hartkamp; Toni M Förster; Sabine Roesner; Catarina Pereira; Arndt Rolfs
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 3.  Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Authors:  Yesim Parman; David Adams; Laura Obici; Lucía Galán; Velina Guergueltcheva; Ole B Suhr; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

Review 4.  Evolving landscape in the management of transthyretin amyloidosis.

Authors:  Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr
Journal:  Ann Med       Date:  2015-11-27       Impact factor: 4.709

Review 5.  Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.

Authors:  Laura Obici; Jan B Kuks; Juan Buades; David Adams; Ole B Suhr; Teresa Coelho; Theodore Kyriakides
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.